PDCD1 and non-small cell lung carcinoma: Interestingly, patients with KRAS+/P53+ NSCLC also showed a remarkable and durable clinical benefit from anti-PD-1 therapy, suggesting a synergistic and complementary effect of both signalling pathways to the TME immunogenicity.